hepat
b
hepb
infect
hepat
b
viru
hbv
attack
liver
caus
acut
chronic
diseas
world
health
organ
estim
million
person
chronic
infect
hbv
peopl
die
everi
year
due
complic
hepb
includ
cirrhosi
liver
cancer
point
need
attent
high
rate
chronic
infect
found
subsaharan
africa
east
asia
adult
popul
infect
well
amazon
southern
part
eastern
central
europ
otherwis
less
popul
western
europ
north
america
chronic
infect
hbv
hepatotrop
dna
viru
replic
revers
transcript
human
hbv
small
circular
dna
molecul
kb
genom
consist
four
partial
overlap
open
read
frame
orf
name
envelop
gene
presurfacesurfac
press
core
gene
precorecor
precc
polymeras
gene
pol
transactiv
protein
x
x
orf
press
encod
surfac
protein
form
surfac
antigen
hbsag
hbsag
protein
main
antigen
elicit
virusneutr
protect
antibodi
immun
system
understand
hbv
genom
structur
essenti
prerequisit
prevent
therapeut
vaccin
hepb
vaccin
hepb
avail
sinc
first
licens
antihbv
vaccin
contain
subvir
particl
hbv
purifi
inactiv
serum
carrier
reveal
high
efficaci
subsequ
subunit
vaccin
made
use
small
surfac
antigen
shbsag
develop
earli
yeast
system
recombin
antigen
ensur
safeti
low
cost
yeastderiv
shbsag
assembl
viruslik
particl
vlp
immunogen
natur
subvir
particl
highli
effect
vaccin
contain
shbsag
wide
use
prophylact
vaccin
hbv
infect
howev
group
vaccin
develop
protect
immun
viru
immunosenesc
frequent
occur
adult
addit
high
cost
limit
necess
accompani
infrastructur
cold
chain
distribut
intraven
administr
still
constitut
barrier
vaccin
approach
develop
countri
order
success
solv
problem
mani
research
project
undertaken
develop
efficaci
easili
administr
thermost
vaccin
new
recombin
hbv
vaccin
contain
press
greater
immunogen
potenti
convent
antigenbas
vaccin
term
antibodi
induct
cellular
immun
respons
middl
mhbsag
larg
lhbsag
surfac
antigen
use
compon
specif
immunotherapeut
vaccin
chronic
hbv
carrier
addit
chimer
protein
creat
fuse
hbv
core
antigen
hbcag
show
strong
antihbc
moder
immun
respons
although
vaccin
one
power
costcompetit
achiev
vaccin
may
still
certain
limit
relat
mainten
cold
chain
downstream
process
cost
administr
risk
expens
scalabl
reason
use
plant
cell
altern
product
platform
receiv
consider
attent
term
intrins
safeti
scalabl
posttransl
modif
target
protein
plant
system
scale
quickli
gener
larg
quantiti
protein
product
suscept
contamin
known
human
mammalian
pathogen
resist
enzymat
digest
gastrointestin
tract
addit
transgen
plant
engin
express
translat
multipl
protein
concurr
appropri
fold
assembl
multimer
protein
especi
posttransl
adjust
antibodi
recombin
antigen
benefit
plantbas
system
best
product
system
recombin
protein
chosen
use
casebycas
approach
merlin
et
al
propos
plant
benefici
product
four
major
categori
pharmaceut
protein
one
requir
larg
quantiti
need
rapidrespons
requir
complex
posttransl
modif
intend
oral
deliveri
within
categori
suggest
appropri
candid
meet
spectrum
research
develop
commerci
need
human
glutam
acid
decarboxylas
norwalk
viruslik
particl
monoclon
antibodi
human
plantmad
antigen
alreadi
test
clinic
trial
success
outcom
tabl
enzym
glucocerebrosidas
gaucher
diseas
first
pmfderiv
enzym
approv
market
protalix
base
use
carrot
cell
produc
recombin
taligluceras
alpha
use
enzym
replac
therapi
treat
adult
patient
special
food
drug
administr
fda
approv
case
fast
track
base
applic
rare
genet
diseas
bioreactor
product
stringent
condit
medicago
ongo
phase
ii
clinic
trial
plantderiv
vlp
quadrival
season
influenza
vaccin
pandem
influenza
vaccin
focus
vlp
vaccin
develop
vlp
selfassembl
structur
deriv
viral
antigen
mimic
nativ
architectur
virus
lack
viral
genom
thu
infect
anoth
import
advantag
emerg
vaccin
effect
activ
key
aspect
immun
respons
achiev
potent
immun
stimul
provid
immunolog
memori
longlast
protect
sever
report
express
properli
assembl
vlp
adequ
level
publish
influenza
viru
human
papillomaviru
human
immunodefici
viru
norwalk
viru
hepat
b
viru
recent
vlp
appli
variou
field
vaccin
also
deliveri
agent
therapeut
medicin
addit
paul
et
al
summar
four
major
develop
molecular
pharmaceut
occur
world
recent
yao
et
al
review
challeng
opportun
plant
molecular
farm
includ
variou
exampl
clinic
trial
perspect
biosafeti
appropri
express
system
possibl
potenti
applic
plantbas
platform
includ
whole
plant
organ
cell
express
technolog
produc
target
antigen
interest
divers
repres
plant
speci
express
oral
vaccin
potato
tomato
tobacco
addit
maiz
rice
carrot
soybean
also
appli
field
plant
mainli
focus
tradit
usual
eaten
crop
human
known
inexperienc
plant
sometim
problem
certain
plant
allergi
target
antigen
protein
express
plant
cell
nuclear
genom
express
system
plant
speci
edibl
plant
vaccin
base
differ
part
plant
fruit
seed
root
veget
food
vaccin
prepar
directli
without
expens
purif
antigen
essenti
requir
parenter
administr
vaccin
therefor
lyophil
organ
express
stabl
antigen
would
facilit
process
purif
storag
reduc
cost
allow
practic
vaccin
although
stabl
transform
transgen
plant
commonli
accept
low
product
level
result
recombin
protein
remain
issu
concern
effici
altern
nuclear
transform
vaccin
antigen
therapeut
protein
plastid
transform
highest
express
transgen
total
solubl
protein
report
chloroplast
transform
otherwis
univers
express
level
studi
total
solubl
protein
tsp
fresh
leaf
tissu
chloroplast
technolog
also
avoid
controversi
relat
transgen
contain
express
multigen
singl
operon
wahe
et
al
review
recent
vaccin
antigen
human
diseas
express
via
plastid
genom
sinc
two
plant
speci
tobacco
differ
antigen
lettuc
four
differ
antigen
mainli
use
plastid
transform
result
suggest
industri
interest
need
strengthen
researchacademiaindustri
linkag
chloroplastbas
vaccin
market
stabl
transform
advantag
reliabl
harvest
target
protein
multipl
gener
optim
protocol
deliveri
foreign
gene
variou
plant
speci
although
problem
time
requir
seed
resourc
grown
anywher
minim
cost
labor
plant
develop
first
time
clinic
trial
except
three
case
eleyso
recombin
human
intrins
factor
use
tobaccobas
transient
express
system
tabl
recent
year
interest
transient
express
increas
due
contain
system
possibl
rapid
upscal
due
short
interv
transform
express
attract
featur
industri
scale
product
approv
express
product
eg
mass
product
tobacco
medicago
kentucki
bioprocess
pogu
et
al
review
plantbas
transient
express
system
product
pharmaceuticalgrad
recombin
aprotinin
monoclon
antibodi
product
transient
express
provid
safe
environment
friendli
system
indoor
outdoor
applic
high
speed
low
cost
genet
manipul
rapid
manufactur
cycl
econom
product
transient
product
use
agrobacterium
tumefaciensmedi
transferdna
deliveri
system
agroinfiltr
andor
virusbas
replic
system
two
domin
approach
guarante
qualiti
result
purifi
product
speed
develop
spiegel
et
al
demonstr
applic
classic
nicotiana
benthamianaa
tumefacien
transient
express
system
acceler
develop
malaria
vaccin
candid
screen
express
solubl
stabil
use
fluoresc
fusion
protein
marin
viega
et
al
transient
express
system
product
human
n
benthamiana
leav
optim
reactiv
plantproduc
cd
screen
test
evalu
henc
transient
express
perform
contain
facil
satisfi
good
manufactur
practic
quick
express
avoid
timeconsum
stabl
transform
comparison
product
term
biomass
product
hiatt
pauli
report
gram
product
may
take
two
week
plu
week
largescal
biomanufactur
system
recombin
protein
produc
level
mgkg
fresh
weight
tissu
littl
three
month
transient
express
human
n
benthamiana
tsp
produc
stabl
express
tobacco
plant
mgg
fresh
weight
fw
convers
express
higher
level
stabl
tobacco
plant
fw
n
benthamiana
fw
result
suggest
express
potenti
level
vari
case
case
depend
target
protein
last
decad
consider
increas
use
transgen
plant
gener
recombin
protein
medic
veterinari
use
tabl
research
group
worldwid
attempt
develop
efficaci
plantderiv
vaccin
diseas
frequent
hepat
b
influenza
case
hepat
b
stabl
transient
express
system
develop
variou
plant
includ
potato
lettuc
tobacco
tomato
carrot
arabidopsi
stabl
express
n
benthamiana
transient
express
detail
review
hepat
b
present
next
part
articl
influenza
also
main
target
field
wide
distribut
viral
infect
human
anim
new
epidem
strain
appear
everi
one
two
year
pattern
requir
product
new
vaccin
frequenc
promis
solut
establish
rapid
flexibl
safe
system
product
variou
antigen
hemagglutinin
ha
extracellular
domain
matrix
protein
mainli
focus
transient
express
system
use
n
benthamiana
leav
use
medicago
system
vaccin
product
initi
within
less
three
week
identif
genet
sequenc
pandem
season
influenza
strain
vamvaka
et
al
report
develop
transgen
rice
plant
express
hivneutr
antibodi
endosperm
dri
seed
weight
evalu
potenti
rice
seed
vehicl
inexpens
microbicid
product
product
higher
initi
achiev
maizederiv
rademach
et
al
rubioinfant
et
al
demonstr
immunogen
potenti
tobacco
chloroplastderiv
multihiv
oral
immun
scheme
propos
vaccin
prototyp
capabl
induc
broad
immun
respons
carri
variou
b
cell
epitop
sever
hiv
strain
dengu
becom
signific
public
health
problem
threat
dengu
fever
increas
temper
region
due
dramat
climat
chang
rice
codonoptim
consensu
domain
iii
dengu
viru
envelop
glycoprotein
e
fuse
cellbind
peptid
via
agroinfiltr
plant
virusbas
express
system
carri
result
step
kim
et
al
gener
ebola
ricbas
denv
vaccin
tobacco
plant
use
geminivir
vector
express
system
report
immunogen
properti
selfadjuv
dengu
vaccin
candid
previous
phoolcharoen
et
al
report
plantexpress
ebola
ric
protect
mice
lethal
ebola
viru
challeng
express
subunit
vaccin
anim
viral
diseas
avian
influenza
footandmouth
diseas
fmd
diarrhea
consid
import
caus
econom
loss
plant
frequent
report
commerci
veterinari
vaccin
rel
easi
compar
human
vaccin
date
four
case
clinic
trial
readi
enter
market
recombin
plant
viral
hamagglutininneuraminidas
hn
protein
newcastl
diseas
viru
approv
unit
state
depart
agricultur
usda
mixtur
antivir
vaccin
prepar
dow
agro
scienc
plant
antirabi
vaccin
complet
phase
develop
thoma
jefferson
univers
chicken
coccidiosi
second
phase
clinic
trial
run
canadian
guardian
bioscienc
compani
fmd
vaccin
n
benthamiana
tomato
rice
use
transient
stabl
transform
recent
muthamilselvan
et
al
present
import
advanc
g
fresh
weight
plant
callusbas
biomass
costeffect
largescal
product
immunopeptid
vaccin
fmd
establish
transgen
cellsuspens
cultur
n
benthamiana
leav
express
fmdv
gene
silenc
suppressor
valid
efficaci
use
immun
guinea
pig
produc
humor
antibodi
lim
et
al
develop
sycmvderiv
vector
contain
fmdv
express
success
soybean
plant
infiltr
diarrhea
repres
infecti
diseas
caus
rotaviru
diarrhea
viru
also
studi
variou
group
express
rotaviru
capsid
protein
plant
studi
introduc
form
intermedi
capsid
vaccin
epitop
differ
plant
speci
includ
n
benthamiana
tomato
medicago
sativa
pera
et
al
suggest
highli
immunogen
epitop
produc
n
benthamiana
candid
subunit
vaccin
specif
rotaviru
strain
greatest
problem
plantderiv
vaccin
develop
extrem
low
express
level
foreign
protein
plant
reason
mani
research
studi
improv
protein
express
level
plant
case
plantderiv
hbv
vaccin
first
report
express
small
hepat
b
surfac
antigen
shbsag
transgen
tobacco
plant
report
hbsag
produc
transgen
tobacco
antigen
physic
similar
hbsag
particl
deriv
human
serum
recombin
yeast
afterward
mani
research
group
attempt
hbsag
express
differ
tissu
plant
speci
tobacco
potato
lettuc
soybean
lupin
maiz
tomato
peanut
laminaria
japonica
tabl
transgen
tobacco
plant
transform
shbsag
gene
control
promot
express
level
low
less
total
solubl
protein
less
ngg
fresh
weight
leaf
tissu
express
level
shbsag
plant
speci
significantli
higher
speci
express
level
even
lower
tobacco
improv
vaccin
product
plant
wide
use
strategi
involv
suitabl
promot
strong
constitut
promot
tissuespecif
promot
promot
induc
environment
factor
target
system
specif
organel
optim
codon
usag
altern
polyadenyl
signal
increas
translat
effici
use
leader
sequenc
differ
vector
system
mani
hbsagoverexpress
transgen
plant
develop
use
strong
constitut
promot
promot
enhanc
addit
tissuespecif
promot
patatin
promot
potato
tuber
globulin
promot
maiz
seed
fruitspecif
promot
use
specif
organel
endoplasm
reticulum
er
vacuol
chloroplasttarget
strategi
also
tri
hbsag
express
noned
plant
tobacco
use
four
differ
express
cassett
hbsag
gene
without
er
retent
signal
hb
hbsag
gene
er
retent
signal
gene
control
ubiquitin
promot
ubq
ethylen
form
enzym
promot
efe
report
maximum
express
level
ngg
fw
leav
observ
efehb
transform
plant
growth
vitro
higher
proport
particul
form
antigen
observ
express
er
retent
signal
efe
promot
effect
vitrocultur
plantlet
wherea
ubq
promot
effect
greenhousegrown
plantlet
maximum
express
level
fw
ubqher
transform
ntl
cell
suspens
cultur
express
level
increas
fw
use
hbsag
fuse
region
soybean
veget
storag
protein
gene
control
chimer
ocsma
promot
upon
transform
soybean
cell
cultur
use
vector
maximum
express
level
fw
hbsag
express
veget
crop
potato
tomato
soybean
lettuc
express
level
transgen
potato
tuber
fw
highest
express
tuber
develop
use
construct
driven
camv
promot
dual
enhanc
tobacco
etch
viru
region
soybean
veget
storag
protein
gene
express
level
hbvprotein
potato
littl
increas
control
tuber
specif
promot
target
dna
insert
genom
dna
random
event
use
agrobacteriummedi
transform
reason
difficult
conclud
best
method
increas
hbvprotein
express
level
differ
express
level
transgen
line
even
vector
construct
express
tomato
fruit
report
dri
weight
achiev
higher
level
express
sever
strong
induc
promot
enhanc
dual
ubq
efe
promot
test
well
organel
target
sequenc
greatest
improv
result
hbsag
gene
er
retent
signal
control
efe
promot
sunil
kumar
et
al
report
hbsag
transform
banana
maximum
express
banana
leav
report
ngg
fw
express
level
banana
fruit
present
report
express
level
presum
lower
leaf
tissu
leafi
veget
varieti
express
technolog
yet
appli
lettuc
maximum
express
level
fw
maximum
antihbsag
antibodi
titer
miu
immun
mice
serum
upon
transform
soybean
cell
cultur
use
construct
hbsag
fuse
region
soybean
veget
storag
protein
gene
control
chimer
ocsma
promot
maximum
express
level
fw
grain
option
express
candid
vaccin
antigen
long
stabil
express
recombin
protein
low
water
content
maiz
seed
maximum
express
report
total
solubl
protein
approxim
fw
level
express
achiev
use
barley
alpha
amylas
signal
sequencefus
shbsag
gene
promot
result
suggest
express
level
hbsag
highli
variabl
depend
plant
speci
tissu
type
cultur
condit
major
recombin
hepat
b
vaccin
contain
shbsag
therefor
express
protein
focu
plant
protein
mhbsag
lhbsag
much
less
studi
shbsag
mhbsag
lhbsag
transform
potato
tomato
tobacco
tabl
although
express
optim
use
suitabl
promot
leader
sequenc
target
signal
express
level
mlhbsag
lower
shbsag
howev
hbcag
induc
heighten
immun
respons
spontan
assembl
capsidlik
particl
reason
effort
devot
product
antihbv
vaccin
focus
hbcag
last
year
especi
hbcag
abundantli
produc
use
transient
express
system
mediat
icon
binari
vector
viral
vector
system
tabl
transgen
tobacco
plantsderiv
hbsag
antigen
physic
similar
human
serum
recombin
yeast
derivedhbsag
particl
analyz
immunolog
respons
vivo
tobaccoexpress
hbsag
purifi
inject
balbc
mice
antihepb
respons
tobaccoderiv
hbsag
qualit
similar
respons
obtain
immun
mice
commerci
yeastderiv
hbsag
vaccin
result
show
possibl
develop
inject
vaccin
use
plantexpress
hbsag
due
differ
manufactur
process
compani
amount
hbsag
protein
per
dose
differ
among
variou
hbv
vaccin
product
reason
intern
standard
hbsag
protein
quantiti
vaccin
standard
base
protect
efficaci
vaccin
relat
antihepb
antibodi
induct
antihbsag
miuml
measur
month
last
dose
vaccin
consid
immun
hepb
although
intern
standard
antigen
concentr
defin
consid
feasibl
costeffect
inject
vaccin
concentr
antigen
despit
mani
attempt
increas
hbsag
express
transgen
plant
express
level
remain
low
use
inject
vaccin
current
use
hbv
vaccin
contain
hbsag
produc
yeast
cell
yeastderiv
hbv
vaccin
suppli
inexpens
per
singl
dose
therefor
difficult
plantderiv
vaccin
competit
price
howev
plant
suspens
cultur
may
use
altern
yeast
produc
antigen
purif
express
level
approach
fw
mgl
cultur
medium
transgen
soybean
cultur
although
express
level
fw
lower
transgen
tobacco
cell
suspens
cultur
soybean
former
use
secret
hbsag
cultur
medium
sixfold
increas
secret
respons
jasmon
acid
salicyl
acid
treatment
cell
cultur
amount
antigen
secret
medium
anoth
breakthrough
regard
express
problem
achiev
util
virusbas
transient
express
system
robust
product
hbv
antigen
shbsag
hbcag
yield
high
mgg
fw
tobaccoderiv
protein
show
maximum
antihbsag
antibodi
titer
miu
immun
mice
serum
prefer
applic
inject
purif
process
rather
oral
administr
order
remov
mani
toxic
alkaloid
phenol
substanc
tobacco
plant
howev
improv
sever
order
magnitud
still
need
plant
cell
cultur
system
competit
particularli
given
slow
growth
rate
plant
cell
compar
yeast
transgen
suspens
cell
cultur
format
vlp
hbv
antigen
made
possibl
exploit
rel
inexpens
protein
purif
techniqu
sucros
gradient
cesium
chlorid
gradient
ultracentrifug
highest
express
soybean
cell
cultur
use
antigen
purif
antigen
suitabl
inject
yield
remain
unsatisfactori
costeffect
biggest
advantag
edibl
plantderiv
vaccin
easi
applic
oral
deliveri
benefit
plantderiv
edibl
vaccin
follow
oral
deliveri
plantderiv
vaccin
protect
stomach
plant
cell
wall
slow
releas
gut
plant
tissu
express
antigen
may
use
raw
dri
food
capsul
also
made
partial
fulli
purifi
vaccin
protein
need
cold
chain
system
storag
deliveri
plant
tissu
extract
plantderiv
vaccin
cost
effici
compar
tradit
vaccin
edibl
plantderiv
hbv
antigen
administ
oral
inject
feed
mice
withwithout
adjuv
oral
vaccin
candid
also
administ
human
volunt
smallscal
clinic
trial
without
adjuv
first
trial
administ
three
human
volunt
row
lettuc
leav
two
dose
shbsagdos
without
use
adjuv
volunt
respond
two
serum
respons
excess
protect
minimum
level
miuml
serum
howev
antibodi
level
declin
rapidli
second
trial
previous
vaccin
human
volunt
fed
two
three
dose
g
raw
potato
tuber
approxim
mg
shbsagdos
half
subject
show
increas
antibodi
titer
anim
experi
trial
show
potenti
plantderiv
hbv
antigen
use
oral
vaccin
prevent
hbv
remain
mani
problem
solv
practic
applic
administr
bulki
plant
materi
declin
longterm
respons
individu
differ
immun
respons
difficulti
defin
antigen
dose
express
level
plantderiv
hbv
antigen
express
yeastderiv
hbv
antigen
howev
express
yield
plant
product
scale
still
increas
tomato
possibl
intak
without
process
cook
therefor
tomato
fruit
attract
crop
develop
oral
vaccin
accord
studi
date
express
level
hbv
antigen
low
ngg
fw
tabl
maximum
titer
antihbsag
antibodi
serum
miu
use
oral
applic
antibodi
yield
high
compar
express
level
hbv
antigen
tomato
fruit
hbv
antigen
express
maiz
produc
much
higher
level
antigen
palat
digest
better
potato
cereal
crop
easili
transport
storag
dri
state
addit
maiz
system
induc
strong
immun
respons
miu
maximum
titer
inject
oral
administr
result
suggest
possibl
provid
raw
materi
thermost
formul
per
dose
plant
compon
saponin
flavonoid
plant
oil
also
function
adjuv
help
maintain
immun
respons
long
term
lyophil
method
excel
way
increas
stabil
shelf
life
plantderiv
vaccin
previou
studi
storag
stabil
lyophil
powder
form
limit
recent
studi
success
longterm
storag
achiev
though
improv
process
easier
control
concentr
standard
antigen
dose
process
antigen
tablet
capsul
form
use
powder
tissu
instead
freezedri
despit
year
effort
commerci
plantbas
antihbv
vaccin
develop
commerci
plantderiv
hbv
vaccin
sever
point
consid
first
greatest
barrier
low
express
level
hbv
antigen
plant
howev
express
yield
plant
product
scale
still
increas
use
plant
express
vector
optim
focus
target
plant
process
also
competit
improv
plantderiv
antigen
increas
immun
respons
vaccin
second
hbv
antigen
express
edibl
plant
advantag
usabl
oral
vaccin
without
process
first
necessari
analyz
characterist
target
plant
express
protein
develop
oral
vaccin
plant
compon
secondari
metabolit
foreign
protein
express
characterist
vari
plant
speci
obtain
feasibl
costeffect
vaccin
target
plant
edibl
vaccin
long
shelf
life
heat
stabl
edibl
raw
materi
candid
grain
crop
maiz
rice
candid
veget
crop
tomato
banana
third
consider
made
public
accept
gm
crop
especi
plantderiv
edibl
vaccin
inject
vaccin
develop
costeffect
method
suspens
cultur
close
environ
accord
regul
good
manufactur
practic
safeti
plantderiv
vaccin
obtain
follow
regul
establish
tradit
vaccin
addit
oral
vaccin
produc
gm
crop
environment
risk
assess
human
risk
assess
perform
reason
plantderiv
oral
vaccin
call
cost
effici
compar
tradit
vaccin
current
concern
use
gm
plant
affect
research
field
